随着跨国药企(MNC)陆续披露2024年业绩,21世纪经济报道记者初步统计发现,自免领域的营收排名中,赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5,年内销售额合计529.31亿美元。 在这5款产品中,度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗,凭借不断拓宽的适应症,成为全球“自免新王”。而乌司奴单抗和阿达木单抗却因受到生物类似药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.